Viral inactivation of intramuscular immune serum globulins

Biologicals

Volumn 28, Issue 1, 2000, Pages 5-15

  Alonso, William R ^a   Trukawinski, Susan ^a   Savage, Margaret ^a   Tenold, Robert A ^a   Hammond, David J ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAMIPINE; BAYGAM; BAYRAB; BAYRHO D; BAYTET; DETERGENT; HEPATITIS B ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; RABIES IMMUNOGLOBULIN; RHESUS D ANTIBODY; TETANUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; FILTRATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; PRECIPITATION; PRIORITY JOURNAL; TOXICOLOGY; VIRUS INACTIVATION;

EID: 0034001594     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1999.0234     Document Type: Article

References (24)

1. Cohn EJ, Strong LE, Hughes WL Jr. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 68:1946;459-475.
2. Oncley JL, Melin M, Richert DA. The separation of antibodies, isoagglutinins, prothrombin, plasminogen and β1-lipoprotein into subfractions of human plasma. J Am Chem Soc. 71:1949;541-550.
3. Wells MA, Wittek AE, Epstein JS. Inactivation and partition of human T-cell lymphotropic virus, type III, during ethanol fractionation of plasma. Transfusion. 26:1986;210-213.
4. Mitra G, Wong MF, Mozen MM. Elimination of infectious retroviruses during preparation of immunoglobulins. Transfusion. 26:1986;394-397.
5. Yei S, Yu MW, Tankersley DL. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion. 32:1992;824-828.
6. Louie RE, Galloway CJ, Dumas ML. Inactivation of Hepatitis C virus in low pH intravenous immunoglobulin. Biologicals. 22:1994;13-19.
7. Horowitz B, Wiebe ME, Lippin A. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion. 25:1985;516-522.
8. Lundblad JL, Seng RL. Inactivation of lipid-enveloped viruses in proteins by caprylate. Vox Sang. 60:1991;75-81.
9. Horowitz B, AM Prince, Horowitz MS. Viral Safety of solvent-detergent treated blood products. Brown F. Virological safety aspects of plasma derivatives. Developments in Biological Standardization. 1993;147-161 Karger, Basel.
10. Prince AM, Horowitz B, Brotman B. Sterilisation of hepatitis and HTL V-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet. 1986;706-710.
11. Edwards CA, Piet MPJ, Chin S. Tri(n-butyl)phosphate detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang. 52:1987;53-59.
12. Page M, Ling C, Dilger P. Fragmentation of Therapeutic Human Immunoglobulin Preparations. Vox Sang. 69:1995;183-194.
13. Painter RH, Walcroft MJ, Weber JCW. The efficacy of fragmented immune serum globulin in passive immunization. Can J Biochem. 44:1965;381.
14. Putnam FW. The Plasma Proteins: Structure, Function and Genetic Control. 1975;Academic Press, New York.
15. Layne E. Spectrophotometric and turbidimetric methods for measuring proteins. III. Biuret method. Colowick K. Methods Enzymol. 3:1975;450-451 Academic Press, New York.
16. Smith, J, Agar, PA, Baer, GM, General methodology for carrying out the REFIT; in Laboratory Techniques in Rabies (WHO), 1973, 5, 254, 257.
17. Cavalli-Sforza L. Biometrie Grundzüge biologisch-medizinischer Statistik [Biometry, the basics of biological and medical statistics]. 1974;Gustav Fischer Verlag, Stuttgart. p. 171-173.
18. Painter RH, Minta JO. Stability of immune serum globulin during storage: Effects of modifications in the fractionation scheme. Vox Sang. 17:1969;434-444.
19. Bundesgesundheitsamt und Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe, Bekanntmachung über die Zulassung von Arzneimitteln.
20. Committee for Proprietary Medicinal Products (CPMP), Note for guidance on virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses, The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, London, 14 February, 1996.
21. Toxicology. 2A:1981.
22. Josephson B, Larsdson H. Acta Med. Scand. 99:1939;140.
23. Wheelwright SM. Protein purification: design and scale up of downstream processing. 1991;Hanser Publishers, Munich. p. 121.
24. Rousell RH, McCue JP. Antibody purification from plasma, Blood Separation and Plasma Fractionation. 1991;Wiley-Liss, Inc. p. 307-340.